Use of multibiomarker disease activity scores in biosimilarity studies for the treatment of patients with rheumatoid arthritis
Objectives This exploratory analysis investigated the potential use of the multibiomarker disease activity (MBDA) score to support biosimilarity assessments using data from two randomised controlled trials (RCTs) of biosimilar infliximab (IFX-qbtx) and biosimilar adalimumab (ADL-afzb) versus EU-sour...
I tiakina i:
| Ngā kaituhi matua: | , , , , , |
|---|---|
| Hōputu: | Artigo |
| Reo: | Inglês |
| I whakaputaina: |
BMJ Publishing Group
2022-11-01
|
| Rangatū: | RMD Open |
| Urunga tuihono: | https://rmdopen.bmj.com/content/8/2/e002423.full |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|